Amrutanjan Health Care Limited
Amrutanjan Health Care Limited manufactures, supplies, and sells ayurvedic pain balms and women hygiene products in India and internationally. It operates through OTC Products, Beverages, Women's Hygiene, and Others segments. The company provides pain management products comprising pain balms and roll-ons, back pain roll-ons, stick-on patch, and joint muscle sprays; dental pain gel; and decorn co… Read more
Amrutanjan Health Care Limited (AMRUTANJAN) - Net Assets
Latest net assets as of September 2025: ₹3.42 Billion INR
Based on the latest financial reports, Amrutanjan Health Care Limited (AMRUTANJAN) has net assets worth ₹3.42 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹4.32 Billion) and total liabilities (₹902.90 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹3.42 Billion |
| % of Total Assets | 79.12% |
| Annual Growth Rate | 16.35% |
| 5-Year Change | 51.52% |
| 10-Year Change | 200.36% |
| Growth Volatility | 56.52 |
Amrutanjan Health Care Limited - Net Assets Trend (2006–2025)
This chart illustrates how Amrutanjan Health Care Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Amrutanjan Health Care Limited (2006–2025)
The table below shows the annual net assets of Amrutanjan Health Care Limited from 2006 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹3.27 Billion | +13.22% |
| 2024-03-31 | ₹2.88 Billion | -0.79% |
| 2023-03-31 | ₹2.91 Billion | +9.67% |
| 2022-03-31 | ₹2.65 Billion | +22.99% |
| 2021-03-31 | ₹2.16 Billion | +35.21% |
| 2020-03-31 | ₹1.59 Billion | +9.39% |
| 2019-03-31 | ₹1.46 Billion | +13.27% |
| 2018-03-31 | ₹1.29 Billion | +1.72% |
| 2017-03-31 | ₹1.26 Billion | +16.32% |
| 2016-03-31 | ₹1.09 Billion | +14.52% |
| 2015-03-31 | ₹949.51 Million | +6.40% |
| 2014-03-31 | ₹892.39 Million | +8.47% |
| 2013-03-31 | ₹822.67 Million | -14.72% |
| 2012-03-31 | ₹964.67 Million | -4.86% |
| 2011-03-31 | ₹1.01 Billion | +5.01% |
| 2010-03-31 | ₹965.51 Million | +3.48% |
| 2009-03-31 | ₹933.00 Million | +258.20% |
| 2008-03-31 | ₹260.47 Million | +11.25% |
| 2007-03-31 | ₹234.13 Million | +27.40% |
| 2006-03-31 | ₹183.78 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Amrutanjan Health Care Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 272956600000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹2.73 Billion | 83.57% |
| Common Stock | ₹28.91 Million | 0.89% |
| Other Comprehensive Income | ₹518.27 Million | 15.87% |
| Total Equity | ₹3.27 Billion | 100.00% |
Amrutanjan Health Care Limited Competitors by Market Cap
The table below lists competitors of Amrutanjan Health Care Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SDT Uzay ve Savunma Teknolojileri A.S.
IS:SDTTR
|
$77.61 Million |
|
STINAG Stuttgart Invest AG
F:STG
|
$77.66 Million |
|
Welldone Co
TWO:6170
|
$77.67 Million |
|
5QQ
F:5QQ
|
$77.72 Million |
|
Xingda International Holdings Limited
F:XDH
|
$77.59 Million |
|
Telia Lietuva AB
F:ZWS
|
$77.57 Million |
|
MaxCyte Inc
NASDAQ:MXCT
|
$77.55 Million |
|
Catella AB A
ST:CAT-A
|
$77.53 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Amrutanjan Health Care Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,884,883,000 to 3,266,146,000, a change of 381,263,000 (13.2%).
- Net income of 508,347,000 contributed positively to equity growth.
- Dividend payments of 132,665,000 reduced retained earnings.
- Share repurchases of 2,378,000 reduced equity.
- New share issuances of 2,378,000 increased equity.
- Other comprehensive income increased equity by 8,258,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹508.35 Million | +15.56% |
| Dividends Paid | ₹132.66 Million | -4.06% |
| Share Repurchases | ₹2.38 Million | -0.07% |
| Share Issuances | ₹2.38 Million | +0.07% |
| Other Comprehensive Income | ₹8.26 Million | +0.25% |
| Other Changes | ₹-2.68 Million | -0.08% |
| Total Change | ₹- | 13.22% |
Book Value vs Market Value Analysis
This analysis compares Amrutanjan Health Care Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.59x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 90.24x to 4.59x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-03-31 | ₹5.74 | ₹518.25 | x |
| 2007-03-31 | ₹7.32 | ₹518.25 | x |
| 2008-03-31 | ₹8.14 | ₹518.25 | x |
| 2009-03-31 | ₹29.34 | ₹518.25 | x |
| 2010-03-31 | ₹31.80 | ₹518.25 | x |
| 2011-03-31 | ₹33.46 | ₹518.25 | x |
| 2012-03-31 | ₹33.00 | ₹518.25 | x |
| 2013-03-31 | ₹28.14 | ₹518.25 | x |
| 2014-03-31 | ₹30.53 | ₹518.25 | x |
| 2015-03-31 | ₹32.48 | ₹518.25 | x |
| 2016-03-31 | ₹37.20 | ₹518.25 | x |
| 2017-03-31 | ₹43.27 | ₹518.25 | x |
| 2018-03-31 | ₹44.01 | ₹518.25 | x |
| 2019-03-31 | ₹49.86 | ₹518.25 | x |
| 2020-03-31 | ₹54.54 | ₹518.25 | x |
| 2021-03-31 | ₹73.73 | ₹518.25 | x |
| 2022-03-31 | ₹90.68 | ₹518.25 | x |
| 2023-03-31 | ₹99.49 | ₹518.25 | x |
| 2024-03-31 | ₹98.87 | ₹518.25 | x |
| 2025-03-31 | ₹112.95 | ₹518.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Amrutanjan Health Care Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 15.56%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 11.28%
- • Asset Turnover: 1.07x
- • Equity Multiplier: 1.29x
- Recent ROE (15.56%) is below the historical average (21.62%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 32.19% | 8.95% | 1.79x | 2.01x | ₹40.79 Million |
| 2007 | 25.26% | 8.17% | 1.75x | 1.77x | ₹35.72 Million |
| 2008 | 19.31% | 6.74% | 1.55x | 1.85x | ₹24.23 Million |
| 2009 | 99.03% | 101.91% | 0.82x | 1.19x | ₹830.64 Million |
| 2010 | 11.88% | 12.78% | 0.76x | 1.23x | ₹18.17 Million |
| 2011 | 10.07% | 9.69% | 0.67x | 1.55x | ₹729.76K |
| 2012 | 9.99% | 6.73% | 1.00x | 1.49x | ₹-116.52K |
| 2013 | 12.30% | 7.40% | 1.10x | 1.51x | ₹18.90 Million |
| 2014 | 13.94% | 8.78% | 1.18x | 1.35x | ₹35.20 Million |
| 2015 | 15.88% | 9.05% | 1.34x | 1.30x | ₹55.79 Million |
| 2016 | 18.92% | 11.02% | 1.33x | 1.29x | ₹97.01 Million |
| 2017 | 16.93% | 9.64% | 1.36x | 1.29x | ₹87.61 Million |
| 2018 | 15.52% | 9.00% | 1.34x | 1.29x | ₹71.07 Million |
| 2019 | 16.82% | 9.73% | 1.34x | 1.29x | ₹99.41 Million |
| 2020 | 15.73% | 9.62% | 1.27x | 1.29x | ₹91.41 Million |
| 2021 | 28.39% | 18.46% | 1.21x | 1.27x | ₹396.34 Million |
| 2022 | 25.34% | 16.57% | 1.16x | 1.32x | ₹406.77 Million |
| 2023 | 13.70% | 10.50% | 1.05x | 1.25x | ₹107.58 Million |
| 2024 | 15.59% | 10.68% | 1.15x | 1.27x | ₹161.24 Million |
| 2025 | 15.56% | 11.28% | 1.07x | 1.29x | ₹181.73 Million |
Industry Comparison
This section compares Amrutanjan Health Care Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $13,504,884,469
- Average return on equity (ROE) among peers: 14.77%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Amrutanjan Health Care Limited (AMRUTANJAN) | ₹3.42 Billion | 32.19% | 0.26x | $77.60 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $802.45 Million | 7.70% | 1.12x | $11.20 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.12 Billion | 12.32% | 2.74x | $149.72 Million |
| Abbott India Limited (ABBOTINDIA) | $42.33 Billion | 33.41% | 0.40x | $1.59 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $15.68 Billion | 32.33% | 0.16x | $1.46 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $123.83 Million |
| Albert David Limited (ALBERTDAVD) | $2.44 Billion | 9.06% | 0.40x | $15.85 Million |
| Alivus Life Sciences Limited (ALIVUS) | $28.17 Billion | 17.24% | 0.21x | $333.13 Million |
| Alkem Laboratories Limited (ALKEM) | $23.74 Billion | 20.90% | 0.71x | $2.41 Billion |
| Alpa Laboratories Limited (ALPA) | $56.73 Million | 0.53% | 2.47x | $5.55 Million |